ECSP12011593A - Análogos de glucagón acilados - Google Patents

Análogos de glucagón acilados

Info

Publication number
ECSP12011593A
ECSP12011593A EC2012011593A ECSP12011593A ECSP12011593A EC SP12011593 A ECSP12011593 A EC SP12011593A EC 2012011593 A EC2012011593 A EC 2012011593A EC SP12011593 A ECSP12011593 A EC SP12011593A EC SP12011593 A ECSP12011593 A EC SP12011593A
Authority
EC
Ecuador
Prior art keywords
accilated
methods
glucagon analogs
peptides
glucagon
Prior art date
Application number
EC2012011593A
Other languages
English (en)
Inventor
Ditte Riber
Eddi Meier
Jens Rosengren Daugaard
Marie Skovgaard
Jakob Lind Tolborg
Gita Kampen
Camila Erteberg Baek
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of ECSP12011593A publication Critical patent/ECSP12011593A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona materiales y procedimientos para promover la pérdida de peso o prevenir el aumento de peso, y en el tratamiento de diabetes y trastornos metabólicos asociados. En particular, la invención proporciona péptidos de análogos de glucagón acilados novedosos eficaces en tales procedimientos. Los péptidos pueden mediar en su efecto teniendo un aumento de la selectividad por el receptor de GLP-1 en comparación con glucagón humano.
EC2012011593A 2009-07-13 2012-01-11 Análogos de glucagón acilados ECSP12011593A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22508009P 2009-07-13 2009-07-13
EP09251780 2009-07-13
EP10157240 2010-03-22
DKPA201000412 2010-05-10

Publications (1)

Publication Number Publication Date
ECSP12011593A true ECSP12011593A (es) 2012-02-29

Family

ID=43448959

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2012011593A ECSP12011593A (es) 2009-07-13 2012-01-11 Análogos de glucagón acilados

Country Status (29)

Country Link
US (3) US9156901B2 (es)
EP (1) EP2454282B1 (es)
JP (1) JP6054742B2 (es)
KR (1) KR101809024B1 (es)
CN (2) CN104961822A (es)
AP (1) AP3329A (es)
AU (1) AU2010272944B2 (es)
CA (1) CA2767792A1 (es)
DK (1) DK2454282T3 (es)
EA (1) EA022816B1 (es)
EC (1) ECSP12011593A (es)
ES (1) ES2537287T3 (es)
GE (1) GEP20146056B (es)
HR (1) HRP20150557T1 (es)
HU (1) HUE026255T2 (es)
IL (1) IL217150A0 (es)
MA (1) MA33517B1 (es)
ME (1) ME02220B (es)
MX (1) MX2012000564A (es)
MY (1) MY188182A (es)
NZ (1) NZ597981A (es)
PE (1) PE20121130A1 (es)
PL (1) PL2454282T3 (es)
PT (1) PT2454282E (es)
RS (1) RS53987B1 (es)
SG (1) SG177609A1 (es)
SI (1) SI2454282T1 (es)
UA (1) UA104766C2 (es)
WO (1) WO2011006497A1 (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110126592A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
WO2010070255A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
PH12012502472A1 (en) 2010-06-24 2013-03-25 Zealand Pharma As Glucagon analogues
KR20140043709A (ko) * 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2012153196A2 (en) 2011-05-10 2012-11-15 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
PE20240686A1 (es) 2011-06-10 2024-04-10 Hanmi Science Co Ltd Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
PE20230404A1 (es) * 2011-06-17 2023-03-07 Hanmi Science Co Ltd Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
RU2610175C2 (ru) 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
WO2013092703A2 (en) * 2011-12-23 2013-06-27 Zealand Pharma A/S Glucagon analogues
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
EP2664374A1 (en) * 2012-05-15 2013-11-20 F. Hoffmann-La Roche AG Lysin-glutamic acid dipeptide derivatives
KR20150023690A (ko) 2012-06-14 2015-03-05 사노피 엑센딘-4 펩타이드 유사체
AU2013295035B2 (en) * 2012-07-23 2017-08-03 Zealand Pharma A/S Glucagon analogues
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PE20151421A1 (es) 2012-11-06 2015-09-24 Hanmi Pharm Ind Co Ltd Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
CN104918961A (zh) 2012-11-20 2015-09-16 梅德瑞斯糖尿病有限责任公司 用于胰岛素抗性的改良的肽药物
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
AU2014230472A1 (en) * 2013-03-14 2015-10-01 Medimmune Limited Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
WO2014147129A1 (en) 2013-03-21 2014-09-25 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
CN105189465B (zh) 2013-03-21 2019-02-26 赛诺菲-安万特德国有限公司 合成含有乙内酰脲的肽产物
WO2014161835A1 (en) 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
MX2016005556A (es) * 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080155A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
WO2015124612A1 (en) * 2014-02-18 2015-08-27 Novo Nordisk A/S Stable glucagon analogues and use for treatment of hypoglycaemia
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
CN117180445A (zh) 2014-05-28 2023-12-08 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN106519015B (zh) 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
MY185334A (en) 2014-12-30 2021-05-06 Hanmi Pharm Ind Co Ltd Glucagon derivatives with improved stability
EA034820B1 (ru) 2015-02-17 2020-03-25 Эли Лилли Энд Компани Порошковый состав для интраназального введения для лечения гипогликемии
AR103954A1 (es) 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
EA201890058A1 (ru) 2015-06-30 2018-07-31 Ханми Фарм. Ко., Лтд. Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2017116204A1 (ko) 2015-12-31 2017-07-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
AR107890A1 (es) 2016-03-10 2018-06-28 Medimmune Ltd Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
CN106084031B (zh) * 2016-06-02 2020-03-31 中国药科大学 一类glp-1r/gcgr双重激动剂在用于降糖和减肥药物中的运用
CN105968186B (zh) * 2016-06-02 2020-10-30 中国药科大学 具有长效化作用的胰高血糖素(Glu)类似物及其应用
EP3468569A4 (en) * 2016-06-09 2020-05-27 AmideBio LLC GLUCAGON ANALOG AND METHOD FOR USE THEREOF
KR102005457B1 (ko) 2016-06-29 2019-07-30 한미약품 주식회사 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
US9994591B2 (en) 2016-08-05 2018-06-12 Boehringer Ingelheim International Gmbh Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
AU2017371516C1 (en) * 2016-12-09 2021-09-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
WO2018104558A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
JP2020500890A (ja) * 2016-12-09 2020-01-16 ジーランド・ファーマ・ア／エス Ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
MX2020007994A (es) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
EP3746449B1 (en) 2018-02-02 2022-03-30 Boehringer Ingelheim International GmbH Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
WO2019149657A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
AU2019215709A1 (en) 2018-02-02 2020-07-16 Boehringer Ingelheim International Gmbh Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
CN110317258B (zh) * 2018-03-29 2023-03-17 齐鲁制药有限公司 一种索玛鲁肽的新多肽片段及其制备方法
US11780900B2 (en) 2018-04-25 2023-10-10 Janssen Sciences Ireland Unlimited Company Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
KR20210109552A (ko) 2018-12-21 2021-09-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 이중특이적 단백질
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
EP4058047A1 (en) 2019-11-11 2022-09-21 Boehringer Ingelheim International GmbH Npy2 receptor agonists
AU2020397917A1 (en) 2019-12-04 2022-06-23 The Scripps Research Institute GLP2 receptor agonists and methods of use
DK4153599T3 (da) 2020-05-22 2024-06-17 Boehringer Ingelheim Int Fremgangsmåde til at fremstille alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridin-carboxylat
ES2991340T3 (es) 2020-05-22 2024-12-03 Boehringer Ingelheim Int Procedimiento continuo de fabricación de 7-amino-5-metil-[1,2,5]oxadiazolo[3,4-b]piridín-carboxilato de alquilo
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2
MX2023014771A (es) 2021-06-09 2024-03-19 Scripps Research Inst Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ202757A (en) 1981-12-23 1985-11-08 Novo Industri As Peptides and medicaments
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
WO1998011126A1 (en) 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
WO1999025727A2 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
JP4394279B2 (ja) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
DE69922043T2 (de) 1998-12-07 2005-11-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Glp-1 analoge
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1956000B1 (en) 1999-03-17 2016-10-05 Novo Nordisk A/S Acylating agents useful for acylating peptides
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
ATE424413T1 (de) 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AU2002346491A1 (en) 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
PL374949A1 (en) 2001-12-20 2005-11-14 Eli Lilly And Company Insulin molecule having protracted time action
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US20060217290A1 (en) 2003-04-29 2006-09-28 Kohn Wayne D Insulin analogs having protracted time action
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP1883419A4 (en) 2005-05-06 2010-08-04 Bayer Pharmaceuticals Corp GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES
RU2485135C2 (ru) 2005-06-13 2013-06-20 Импиэриэл Инноувейшнс Лимитид Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
WO2007024899A2 (en) 2005-08-23 2007-03-01 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
CN101389648B (zh) 2006-02-22 2013-07-17 默沙东公司 肽胃泌酸调节素衍生物
ES2673822T3 (es) 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
ITMI20061607A1 (it) 2006-08-09 2008-02-10 Maria Vincenza Carriero Peptidi con attivita farmacologica
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
EP2025684A1 (en) 2007-08-15 2009-02-18 Zealand Pharma A/S Glucagon analogues
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
EP2229406B1 (de) 2008-01-09 2015-04-22 Sanofi-Aventis Deutschland GmbH Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
RU2010147076A (ru) 2008-04-22 2012-05-27 Кейз Вестерн Ризев Юнивесити (Us) Аналоги инсулина специфичные к изоформам
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
EP2300037B1 (en) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2009155257A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
DK2300035T3 (en) 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
CA2732439A1 (en) 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin
KR101417873B1 (ko) 2008-08-07 2014-07-09 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
WO2010070255A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
KR20110126592A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
WO2010080609A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
WO2010107487A2 (en) 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
BR112012018104A2 (pt) 2010-01-20 2017-10-17 Zeland Pharma As tratamento de doenças cardíacas
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
EP2552952A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
BR112012027545B1 (pt) 2010-04-27 2020-09-24 Betta Pharmaceuticals Co., Ltd. Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
PH12012502472A1 (en) 2010-06-24 2013-03-25 Zealand Pharma As Glucagon analogues
EP2637698B1 (en) 2010-11-09 2022-04-20 Novo Nordisk A/S Double-acylated glp-1 derivatives
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
JP2014510739A (ja) 2011-03-28 2014-05-01 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
RU2602601C2 (ru) 2011-04-12 2016-11-20 Ново Нордиск А/С Дважды ацилированные производные glp-1
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2012153196A2 (en) 2011-05-10 2012-11-15 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2012167744A1 (en) 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
RU2610175C2 (ru) 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
WO2013092703A2 (en) 2011-12-23 2013-06-27 Zealand Pharma A/S Glucagon analogues
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
AU2013295035B2 (en) 2012-07-23 2017-08-03 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MX2016005556A (es) 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
WO2015124612A1 (en) 2014-02-18 2015-08-27 Novo Nordisk A/S Stable glucagon analogues and use for treatment of hypoglycaemia
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue

Also Published As

Publication number Publication date
US20120178670A1 (en) 2012-07-12
ME02220B (me) 2016-02-20
US20190076506A1 (en) 2019-03-14
EA022816B1 (ru) 2016-03-31
MA33517B1 (fr) 2012-08-01
IL217150A0 (en) 2012-02-29
CA2767792A1 (en) 2011-01-20
GEP20146056B (en) 2014-03-10
NZ597981A (en) 2014-02-28
WO2011006497A1 (en) 2011-01-20
AP3329A (en) 2015-06-30
HUE026255T2 (en) 2016-06-28
AU2010272944A1 (en) 2012-02-23
EP2454282B1 (en) 2015-03-04
CN104961822A (zh) 2015-10-07
US20160120951A1 (en) 2016-05-05
PT2454282E (pt) 2015-06-23
JP2012532898A (ja) 2012-12-20
US10004786B2 (en) 2018-06-26
PE20121130A1 (es) 2012-08-30
PL2454282T3 (pl) 2015-08-31
ES2537287T3 (es) 2015-06-05
KR20120052973A (ko) 2012-05-24
CN102574903A (zh) 2012-07-11
MX2012000564A (es) 2012-04-11
HRP20150557T1 (xx) 2015-07-03
RS53987B1 (sr) 2015-10-30
MY188182A (en) 2021-11-24
CN102574903B (zh) 2015-07-08
HK1171035A1 (en) 2013-03-15
JP6054742B2 (ja) 2016-12-27
UA104766C2 (uk) 2014-03-11
US9156901B2 (en) 2015-10-13
AU2010272944B2 (en) 2015-11-19
SI2454282T1 (sl) 2015-06-30
EA201290027A1 (ru) 2013-01-30
KR101809024B1 (ko) 2017-12-14
SG177609A1 (en) 2012-02-28
DK2454282T3 (en) 2015-05-04
AP2012006107A0 (en) 2012-02-29
EP2454282A1 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
ECSP12011593A (es) Análogos de glucagón acilados
UY35030A (es) Análogos de glucagón
UY33462A (es) Analogos de glucagon
ECSP12012357A (es) Análogos del glucagón
MX2016004461A (es) Analogos de glucagon acilados.
MX2016004907A (es) Analogos del glucagon.
MX372841B (es) Análogo acilado del glucagón.
MX2011006315A (es) Analogos de glucagon.
CL2014003421A1 (es) Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad.
MX2011006320A (es) Analogos de glucagon.
TN2011000295A1 (en) Glucagon analogues
MX2011006314A (es) Analogos de glucagon.
CO6382136A2 (es) Análogos de glucagón
ECSP15009978A (es) Análogos de glucagón
TN2011000667A1 (en) Acylated glucagon analogues
CY1116448T1 (el) Ακυλιωμενα αναλογα γλυκαγονης